Chugai Seiyaku Kabushiki Kaisha

Yoshiyuki Furuta

Yoshikazu Nishimura

Tsutomu Sato

Satoshi Tsuchiya

Masahiro Nishimoto

Atsushi Matsuo

Hirotaka Kashiwagi

Hitoshi Yoshino

Nobuyuki Hori

Masahide Aoki

Satoshi Tanida

Takahiro Kawai

Shoshin Yoshida

Takuma Kamon

Kyoko Oguri

Hiroko Ogawa

Takuya Shiraishi

Naoki Okamoto

Toru Esaki

Yoshiaki Isshiki

Masateru Ohta

Akemi Mizutani

Tomoya Kotake

Wayne Wen Lai

The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Pyrazolopyridine derivative having GLP-1 receptor agonist effect

The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R, R, R, R, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

Spiroimidazolone derivative

Growing community of inventors

Shizuoka, Japan

Yoshiyuki Furuta